Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $114.75 | Total: $573.75 |
| 1 | 10 | $97.20 | Total: $972.00 |
| 1 | 25 | $82.35 | Total: $2,058.75 |
| 1 | 50 | $70.20 | Total: $3,510.00 |
| 1 | 100 | $60.75 | Total: $6,075.00 |
Overview
ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).
Chemical Properties
| Molecular Formula | C22H19ClO6 |
| Molecular Weight | 414.84 |
| CAS Numbers | 2919019-72-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C(O)C1CC(OCCOC=2C=CC(=CC2)C=3OC=4C(Cl)=CC=CC4C(=O)C3)C1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Wang L, et al. Discovery of a first-in-class orally available HBV cccDNA inhibitor. J Hepatol. 2022 Dec 29 S0168-8278[22]03466-3.